Abstract
The COVID-19 pandemic of 2020 prompted stringent mitigation measures to “flatten the curve” quickly leading to an asphyxiated US economy as a national side effect. The resulting flattened curve remain exponential and may still exceed available healthcare resources and capacity during and around its peak. Moreover, while isolation and containment can scale down daily cases significantly, such a mitigation strategy also prolong the outbreak. Since economic activity is inversely proportional to mitigation, curtailing the outbreak with sustained mitigation can stifle the economy severely having disasterous repercussions. Mitigation for the duration of the outbreak may therefore be unsustainable and risk a second wave of infections. The method for active pandemic curve management (MAPCM) presented herein has the potential to shape the outbreak curve in a controlled manner for optimal utilization of healthcare resources during the pandemic, while drastically shortening the outbreak duration compared to mitigation by itself without trading off lives. This method allows mitigation measures to be relaxed gradually from day one, which equates to the ramping up of economic activity, and it leaves breathing room for the economy from the onset of a pandemic. Since outbreak curves (such as projected hospitalizations per day) can be programmed using this method, they can also be shaped to accommodate changing needs during the outbreak. To be successful the method must be implemented early enough in the outbreak. Implementing the method incorrectly can result in a herd immunity levels of infections. MAPCM is a method and not a model. It is compatible with any appropriate model. In the paper a hybrid logistic model is used for illustration.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
There were no trials in the study.
Funding Statement
This work was not funded
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is publicly available and has been widely distributed.
